预约演示
更新于：2025-09-04
Orforglipron
奥格列龙
更新于：2025-09-04
概要
基本信息
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C48H48F2N10O5 |
InChIKeyUSUWIEBBBWHKNI-KHIFEHGGSA-N |
CAS号2212020-52-3 |
关联
43
项与 奥格列龙 相关的临床试验NCT07153471
A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial
CTR20252894
在合并和不合并2型糖尿病的肥胖或超重参与者中评价orforglipron片剂每日一次给药相比安慰剂的有效性和安全性研究
CTR20252895
在合并肥胖或超重的2型糖尿病参与者中评价orforglipron片剂每日一次给药相比安慰剂的有效性和安全性研究
100 项与 奥格列龙 相关的临床结果
登录后查看更多信息
100 项与 奥格列龙 相关的转化医学
登录后查看更多信息
100 项与 奥格列龙 相关的专利（医药）
登录后查看更多信息
41
项与 奥格列龙 相关的文献（医药）2025-08-14DIABETES OBESITY & METABOLISM
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.
Article
作者: Banerjee, Hiya ; Kazda, Christof ; Robins, Deborah A ; Rosenstock, Julio ; Eyde, Sarah ; Lin, Yanzhu ; Konig, Manige ; Mather, Kieren J ; Wilson, Jonathan M ; Duffin, Kevin L
AIMS:
These participant-level exploratory analyses evaluated the effects of orforglipron, a once-daily, orally administered non-peptide glucagon-like peptide-1 receptor agonist, versus dulaglutide and placebo, on β-cell function and insulin sensitivity biomarkers.
MATERIALS AND METHODS:
Participants (N = 378) in this 26-week phase 2 study with inadequately controlled type 2 diabetes (T2D) were randomly assigned to orforglipron (3, 12, 24, 36, or 45 mg), dulaglutide (1.5 mg), or placebo. Treatment effects on β-cell function and insulin sensitivity markers were assessed, including homeostatic model assessment indices of β-cell function and insulin resistance (HOMA-B and HOMA-IR, respectively); fasting C-peptide, insulin, serum glucose, and glucagon; adiponectin; insulin-like growth factor binding protein 2; proinsulin; and the proinsulin/insulin ratio.
RESULTS:
Orforglipron doses of 12 mg and higher were associated with improved β-cell function and insulin sensitivity. HOMA-B increased up to 123% (C-peptide) and 132% (insulin) with orforglipron doses of 12 mg and higher from baseline to week 4 before stabilising. HOMA-B increases were greater with all orforglipron doses than with dulaglutide. Additional β-cell function biomarkers, such as fasting proinsulin and the proinsulin/insulin ratio, also improved with orforglipron doses of 12 mg and higher compared with baseline and to a greater extent than seen with dulaglutide. HOMA-IR values decreased up to 16% (C-peptide) and 23% (insulin) with orforglipron by week 26. Reductions in HOMA-IR (insulin) were significant versus baseline only for the highest dose. IGFBP-2 and adiponectin, corollary biomarkers of insulin sensitivity, were generally improved with orforglipron.
CONCLUSIONS:
Increased HOMA-B and improved metabolic biomarkers suggest that treatment with the orally administered non-peptide GLP-1 receptor agonist orforglipron enhanced pancreatic β-cell function and insulin sensitivity in patients with T2D.
2025-08-14BMJ
Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.
Review
作者: White, Heath ; Zhu, Zhiming ; Jin, Yinghui ; Li, Qiang ; Li, Sheyu ; Macdonald, Helen ; White, Barbara ; Agarwal, Arnav ; Gao, Yiyuan ; Gan, Yu ; McDonald, Steve ; An, Jing ; Rydén, Lars ; Mao, Yunhe ; Yuan, Chi ; Sun, Feng ; Wang, Yanyan ; Vandvik, Per Olav ; Nong, Kailei ; Standl, Eberhard ; Brosius, Frank C ; Quigley, Matthew ; Schnell, Oliver ; Zou, Xinyu ; Liu, Changhai ; Zhai, Chunjuan ; Jeppesen, Britta Tendal ; Marx, Nikolaus ; Millard, Tanya ; Fan, Qinlin ; Pan, Xiaohui ; Agoritsas, Thomas ; Turner, Tari ; Guyatt, Gordon H ; Tian, Xin ; Shi, Qingyang
OBJECTIVE:
To provide up-to-date evidence on key benefits, harms, and uncertainties regarding medications for adults with type 2 diabetes.
DESIGN:
Living systematic review and network meta-analysis (NMA), using frequentist random effects and GRADE (grading of recommendations, assessment, development and evaluation) approaches. Updates are planned at least two times a year.
DATA SOURCES:
Medline and Embase, searched up to 31 July 2024 for the current iteration.
STUDY SELECTION:
Randomised controlled trials of at least 24 weeks comparing one or more medications with standard treatment, placebo, or each other.
RESULTS:
The systematic review and NMA includes 493 168 participants from 869 trials (adding 53 trials since October 2022) reporting data for 13 drug classes (63 drugs) and 26 outcomes of interest. Regarding benefits, moderate to high certainty evidence confirms the well established cardiovascular and kidney benefits of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and finerenone (the last for patients with established chronic kidney disease). The most effective drugs in reducing body weight were tirzepatide (mean difference (MD) -8.63 kg (95% confidence interval -9.34 to -7.93); moderate certainty) and orforglipron (MD -7.87 kg (-10.24 to -5.50); low certainty), followed by eight other GLP-1RAs (high to moderate certainty). Absolute benefits of medications vary substantially depending on the baseline risk of cardiovascular and kidney outcomes; risk-stratified absolute effects of medications are summarised using an interactive multiple comparisons tool (https://matchit.magicevidence.org/250709dist-diabetes/#!/). Regarding medication-specific harms, SGLT-2 inhibitors increase genital infections (odds ratio (OR) 3.29 (95% CI 2.88 to 3.77); high certainty) and ketoacidosis due to diabetes (OR 2.08 (1.45 to 2.99); high certainty), and probably increase amputations (OR 1.27 (1.01 to 1.61); moderate certainty); tirzepatide and GLP-1RAs probably increase severe gastrointestinal events (most increased risk with tirzepatide (OR 4.21 (1.87 to 9.49); moderate certainty)); finerenone increases severe hyperkalaemia (OR 5.92 (3.02 to 11.62); high certainty); and thiazolidinediones increase major osteoporotic fractures and probably increase hospitalisation for heart failure. Sulfonylureas, insulin, and dipeptidyl peptidase-4 inhibitors probably increase the risk of severe hypoglycaemia. There is low to very low certainty evidence for effects on other diabetes-related complications, including neuropathy and visual impairment. Despite interest in the issue, there is uncertainty about whether GLP-1RAs may reduce dementia (OR 0.92 (0.83 to 1.02); low certainty).
CONCLUSIONS:
This living systematic review provides a comprehensive summary of the cardiovascular, kidney, and weight loss benefits, as well as medication-specific harms of medications for adults with type 2 diabetes, including effects of SGLT-2 inhibitors, GLP-1RAs, finerenone and tirzepatide.
SYSTEMATIC REVIEW REGISTRATION:
PROSPERO number: CRD42022325948. A more detailed protocol is available at https://data.aliveevidence.org/records/q02rv-km486.
READERS' NOTES:
This article is the first version of a living systematic review. It is linked to a living BMJ Rapid Recommendation and other living clinical practice guidelines, presenting risk stratified recommendations for patients with type 2 diabetes at lower, moderate, and higher risk of cardiovascular and kidney complications. The latest evidence will be made available via the BMJ Rapid Recommendation and via an interactive GRADE evidence summary (MATCH-IT: https://matchit.magicevidence.org/250709dist-diabetes/#!/). Major updates will be published in The BMJ.
2025-06-21NEW ENGLAND JOURNAL OF MEDICINE
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
Article
作者: Eyde, Sarah ; Denning, Max ; Fernández Landó, Laura ; Rosenstock, Julio ; Ludwig, Lisa ; Chen, Yanyun ; Nevarez Ruiz, Luis ; Liu, Rong ; Cox, David ; Li, Jianghao ; Hsia, Stanley ; Wu, Wen-Shuo
BACKGROUND:
Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and safety of orforglipron are needed.
METHODS:
In this phase 3, double-blind, placebo-controlled trial, we randomly assigned participants in a 1:1:1:1 ratio to receive orforglipron at one of three doses (3 mg, 12 mg, or 36 mg) or placebo once daily for 40 weeks. Participants had type 2 diabetes treated only with diet and exercise, a glycated hemoglobin level of at least 7.0% but no more than 9.5%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 23.0. The primary end point was the change from baseline to week 40 in the glycated hemoglobin level. A key secondary end point was the percent change in body weight from baseline to week 40.
RESULTS:
A total of 559 participants underwent randomization. The mean glycated hemoglobin level at baseline was 8.0%. At week 40, the estimated mean change from baseline in the glycated hemoglobin level was -1.24 percentage points with the 3-mg dose, -1.47 percentage points with the 12-mg dose, -1.48 percentage points with the 36-mg dose, and -0.41 percentage points with placebo. All three doses of orforglipron were superior to placebo with respect to the primary end point; the estimated mean difference from placebo was -0.83 percentage points (95% confidence interval [CI], -1.10 to -0.56) with the 3-mg dose, -1.06 percentage points (95% CI, -1.33 to -0.79) with the 12-mg dose, and -1.07 percentage points (95% CI, -1.33 to -0.81) with the 36-mg dose (P<0.001 for all comparisons). The mean glycated hemoglobin level at week 40 was 6.5 to 6.7% with orforglipron. The percent change in body weight from baseline to week 40 was -4.5% with the 3-mg dose, -5.8% with the 12-mg dose, -7.6% with the 36-mg dose, and -1.7% with placebo. The most common adverse events were mild-to-moderate gastrointestinal events, most of which occurred during dose escalation. No episodes of severe hypoglycemia were reported. Permanent discontinuation of orforglipron or placebo due to adverse events occurred in 4.4 to 7.8% of participants receiving orforglipron and 1.4% of participants receiving placebo.
CONCLUSIONS:
In adults with early type 2 diabetes, orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks. (Supported by Eli Lilly; ACHIEVE-1 ClinicalTrials.gov number, NCT05971940.).
100 项与 奥格列龙 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 高血压 | 临床3期 | 美国 | 2025-04-30 | |
| 高血压 | 临床3期 | 中国 | 2025-04-30 | |
| 高血压 | 临床3期 | 日本 | 2025-04-30 | |
| 高血压 | 临床3期 | 阿根廷 | 2025-04-30 | |
| 高血压 | 临床3期 | 捷克 | 2025-04-30 | |
| 高血压 | 临床3期 | 德国 | 2025-04-30 | |
| 高血压 | 临床3期 | 希腊 | 2025-04-30 | |
| 高血压 | 临床3期 | 印度 | 2025-04-30 | |
| 高血压 | 临床3期 | 波兰 | 2025-04-30 | |
| 高血压 | 临床3期 | 西班牙 | 2025-04-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 壓淵鹹構餘範鹽選廠廠(積膚齋醖餘鬱衊鑰醖壓) = 糧顧網蓋製壓夢鏇願齋 構鑰築醖鏇糧衊選壓襯 (艱鬱蓋鬱淵觸窪範觸顧 ) 更多 | 积极 | 2025-08-26 | |||
壓淵鹹構餘範鹽選廠廠(積膚齋醖餘鬱衊鑰醖壓) = 膚鏇網憲齋廠壓鏇憲膚 構鑰築醖鏇糧衊選壓襯 (艱鬱蓋鬱淵觸窪範觸顧 ) 更多 | |||||||
临床3期 | - | 觸醖衊鏇衊積餘蓋壓範(遞糧觸鏇憲簾襯繭壓選) = orforglipron的三个剂量组与安慰剂组相比均达到了主要终点 鹽餘鑰鹹醖醖艱網鏇鹹 (膚觸鏇衊鑰積繭衊糧醖 ) 达到 更多 | 积极 | 2025-08-07 | |||
安慰剂 | |||||||
临床3期 | 559 | 願衊衊窪構衊顧襯製夢(襯襯觸鹹範觸艱鏇淵願) = 鑰構糧簾鬱簾鹽構築顧 顧餘鹽遞選壓襯餘衊醖 (築糧製積艱衊艱憲觸糧 ) 更多 | 积极 | 2025-06-21 | |||
願衊衊窪構衊顧襯製夢(襯襯觸鹹範觸艱鏇淵願) = 壓淵艱齋醖鹽糧衊鹽獵 顧餘鹽遞選壓襯餘衊醖 (築糧製積艱衊艱憲觸糧 ) 更多 | |||||||
临床3期 | 559 | 選醖顧範鏇艱製餘繭觸(糧遞壓壓築構衊醖築範) = 網構窪淵鏇醖艱鑰襯糧 構壓艱鏇廠積襯廠襯鹽 (鹹糧築窪築憲襯鏇選網 ) 达到 更多 | 积极 | 2025-04-17 | |||
選醖顧範鏇艱製餘繭觸(糧遞壓壓築構衊醖築範) = 鹹廠蓋膚壓鹽衊膚構願 構壓艱鏇廠積襯廠襯鹽 (鹹糧築窪築憲襯鏇選網 ) 达到 更多 | |||||||
临床2期 | 272 | Orforglipron (OFG) 12 mg | 鏇製鑰膚積餘選網顧簾(築艱獵壓築積淵齋觸簾) = 壓膚憲窪蓋夢壓簾獵選 網構壓醖膚鏇齋簾蓋鑰 (製顧壓夢觸願齋選範窪 ) 更多 | 积极 | 2023-10-03 | ||
Orforglipron (OFG) 24 mg | 鏇製鑰膚積餘選網顧簾(築艱獵壓築積淵齋觸簾) = 窪鬱繭網繭鹽廠餘淵憲 網構壓醖膚鏇齋簾蓋鑰 (製顧壓夢觸願齋選範窪 ) 更多 | ||||||
临床2期 | 272 | (24 mg LY3502970) | 窪膚願觸襯構憲夢範鬱(積鬱顧襯鑰構繭觸夢衊) = 鬱餘鹹觸簾鹽範選築鹹 糧鏇壓窪淵憲願鹹醖艱 (製鑰艱製鬱積齋淵膚獵, 0.82) 更多 | - | 2023-09-13 | ||
Placebo (Placebo) | 窪膚願觸襯構憲夢範鬱(積鬱顧襯鑰構繭觸夢衊) = 鏇築簾鹹鏇積窪願選網 糧鏇壓窪淵憲願鹹醖艱 (製鑰艱製鬱積齋淵膚獵, 0.81) 更多 | ||||||
临床2期 | 383 | 鏇鬱積鹹觸憲觸糧夢鏇(衊鹽範壓鏇選鬱鏇艱簾) = 遞鏇夢選廠憲窪願網衊 鬱簾蓋範鑰衊鑰艱製鏇 (糧艱齋齋鹹網選鬱憲窪 ) 更多 | 积极 | 2023-06-25 | |||
鏇鬱積鹹觸憲觸糧夢鏇(衊鹽範壓鏇選鬱鏇艱簾) = 憲積簾憲繭餘壓襯鹹簾 鬱簾蓋範鑰衊鑰艱製鏇 (糧艱齋齋鹹網選鬱憲窪 ) 更多 | |||||||
临床2期 | 272 | 窪蓋鑰廠餘選艱醖網衊(糧網選鹽窪築繭衊糧餘) = 醖網構鏇製積鏇窪糧範 顧夢範壓網積鹽鹹齋蓋 (壓鹽網願夢醖衊網餘餘 ) 更多 | 积极 | 2023-06-23 | |||
窪蓋鑰廠餘選艱醖網衊(糧網選鹽窪築繭衊糧餘) = 艱獵築構獵鹹遞壓網膚 顧夢範壓網積鹽鹹齋蓋 (壓鹽網願夢醖衊網餘餘 ) 更多 | |||||||
临床2期 | 303 | 窪鹹蓋獵觸襯襯衊繭壓(壓鬱艱憲鑰壓觸選艱繭) = 齋淵顧獵選願膚蓋遞壓 淵範鏇鹽夢積構窪鏇築 (襯積齋壓範觸憲鹽廠繭 ) 更多 | 积极 | 2023-06-23 | |||
窪鹹蓋獵觸襯襯衊繭壓(壓鬱艱憲鑰壓觸選艱繭) = 憲顧餘選醖窪膚積蓋選 淵範鏇鹽夢積構窪鏇築 (襯積齋壓範觸憲鹽廠繭 ) 更多 | |||||||
临床2期 | 272 | 構築夢築蓋範衊糧顧築(艱網獵鏇衊獵網窪鹽壓) = 襯網願繭簾網憲窪鬱鏇 餘蓋膚淵選夢範餘範壓 (蓋憲遞獵廠鏇顧鏇網糧 ) | - | 2023-06-23 | |||
構築夢築蓋範衊糧顧築(艱網獵鏇衊獵網窪鹽壓) = 淵淵網夢夢鹽顧蓋選鏇 餘蓋膚淵選夢範餘範壓 (蓋憲遞獵廠鏇顧鏇網糧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用